Al-Ali Haifa Kathrin - Department of Hematology/Oncology/Hemostasiology, University of Leipzig, Johannisallee 32 A, 04103 Leipzig, Germany.

基本信息

浏览量：95

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 258 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML

Marcus Bauer,Nadja Jaekel, Andreas Wilfer,Anja Haak, Markus Eszlinger,Katalin Kelemen,Monika Haemmerle,Haifa Kathrin Al-Ali,Barbara Seliger,Claudia Wickenhauser

ONCOIMMUNOLOGYno. 1 (2024): 2323212-2323212

引用0浏览0WOS引用

FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)

Susanne Isfort, Nikolas von Bubnoff,Haifa Kathrin Al-Ali,Heiko Becker, Thorsten Götze, Philipp le Coutre,Martin Griesshammer, Claudia Moskwa, Luisa Wohn, Johanna Riedel, Francesca Palandri, Kirsi Manz,

Annals of Hematologypp.1-11, (2024)

引用0浏览0引用

ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options

Jean-Jacques Kiladjian, Francisca Ferrer Marin,Haifa Kathrin Al-Ali,Alberto Alvarez-Larrán,Eloise Beggiato,Maria Bieniaszewska, Massimo Breccia,Veronika Buxhofer-Ausch,Olga Cerna, Ana-Manuela Crisan,Catalin Doru Danaila,Valerio De Stefano,

Annals of Hematology（2024）

引用0浏览0WOS引用

Annals of hematology (2024)

引用0浏览0WOS引用

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

David Lavie,Vincent Ribrag, Michael Loschi,Costas K. Yannakou, Maan Alwan, Adi Schacham Abulafia,Jesús María Hernández-Rivas,Yulia Volchek,Chun Yew Fong,Massimiliano Bonifacio,Jean-Jacques Kiladjian,Jean-Christophe Ianotto,

Blood (2023): 623

引用0浏览0引用

S214: disease-modifying activity of navtemadlin (nvtm) correlated with survival outcomes in janus kinase inhibitor (jaki) relapsed or refractory (r/r) myelofibrosis (mf) patients (pts)

Pankit Vachhani,Andrew Perkins,John Mascarenhas,Haifa Kathrin Al‐Ali,Jean‐Jacques Kiladjian, Sonia Cerquozzi, Jarosław Dybko,Regina García Delgado,Jesus Hernández Rivas,Holger Hebart, Zhujun Huang,Cecile M. Krejsa,

HemaSphereno. S3 (2023): e05521ca-e05521ca

引用0浏览0引用

MDS-641 Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis

Guillermo Garcia-Manero,Kimo Bachiashvili,Elizabeth A. Griffiths,Amer M. Zeidan,Elie Traer,Lalit Saini,Harshad Amin,Sanjay Mohan,Michael Lubbert,Lori Maness-Harris,James Foran,Dominik Selleslag,

Clinical Lymphoma, Myeloma & Leukemia (2023): S376-S377

引用0浏览0引用

POSTER: MDS-641 Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis

Guillermo Garcia-Manero,Kimo Bachiashvili,Elizabeth A. Griffiths,Amer M. Zeidan,Elie Traer,Lalit Saini,Harshad Amin,Sanjay Mohan,Michael Lubbert,Lori Maness-Harris,James Foran,Dominik Selleslag,

Clinical Lymphoma Myeloma and Leukemia (2023): S187

引用0浏览0引用

Pb2185: effect of new or worsening anemia on clinical outcomes in patients with myelofibrosis (mf) treated with ruxolitinib (rux): a post hoc analysis of the comfort-i and -ii trials

Haifa Kathrin Al‐Ali,Ruben A. Mesa, Jennifer E. Hamer-Maansson,Evan Braunstein,Claire Harrison

HemaSphereno. S3 (2023): e85817f0-e85817f0

引用0浏览0引用

Erratum zu: Patient-Reported Outcomes in klinischer Praxis

Thomas Nordhausen, Dirk Vordermark,Haifa-Kathrin Al-Ali,Heike Schmidt

best practice onkologieno. 1-2 (2023): 59-60

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn